ELISPOT Assay for Aspergillus-Specific T Cell Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for invasive aspergillosis are invasive, slow, non-sensitive, lack standardization, and have variable kinetics, limiting their effectiveness in clinical settings, particularly in patients with malignant hemopathies undergoing chemotherapy.
Innovation Solution
An in vitro immunoenzymatic ELISPOT assay is used to detect Aspergillus-specific T cells by placing patient-derived biological fluid in contact with an antigen extract from Aspergillus fumigatus, specifically identifying and counting IFN-γ and IL-10 producer T cells to determine the infection risk, with threshold values for diagnosis set between 15-25 SFCs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diagnostic methods (histological exam, culture exam, HRCT, serologic exams, PCR) are used, then diagnostic confirmation can be obtained, but the methods are invasive, slow, have low sensitivity, lack standardization, and have variable kinetics
Solution Approach 1:
The patent replaces complex mechanical and procedural diagnostic systems (histological exams, culture exams, HRCT, serologic exams, PCR) with an immunoenzymatic ELISPOT assay that detects T-cell responses. This substitution simplifies the diagnostic workflow while maintaining or improving reliability through objective quantification of immune responses to Aspergillus antigens.
Solution Approach 2:
The patent changes the diagnostic parameter from direct detection of fungal presence (culture, histology) or fungal markers (galactomannan, beta-glucan, PCR) to detection of host immune response parameters (T-cell frequency, IFN-γ production, IL-10 production). This parameter change enables standardized, sensitive detection without the limitations of previous methods.
2Reliability
If invasive diagnostic procedures are performed to confirm IA, then absolute diagnosis can be obtained, but patient burden and diagnostic speed are reduced
Solution Approach 1:
The ELISPOT assay performs preliminary detection of T-cell responses to Aspergillus antigens before invasive procedures are needed. By detecting specific immune responses in peripheral blood, the assay provides early diagnostic information that can guide whether invasive confirmation is necessary, reducing overall diagnostic time and patient burden.
Solution Approach 2:
The patent uses the patient's own T cells as an intermediary marker to indirectly detect Aspergillus infection. Instead of directly observing the fungus or its effects on tissue, the assay measures the immune system's response to fungal antigens, providing a non-invasive window into the infection status.
3Measurement precision
If standard diagnostic methods are used, then diagnostic procedures can be performed, but sensitivity and early detection capability are limited
Solution Approach 1:
The ELISPOT assay creates a detectable copy of the immune response through spot formation on the membrane. Each spot represents a T cell that has secreted cytokine in response to Aspergillus antigen, providing an amplified, visible copy of the immune response that is highly sensitive and suitable for automated counting and analysis.
Solution Approach 2:
The assay uses colorimetric detection where cytokine-secreting cells produce visible spots through enzymatic reaction with substrate. This color change provides a sensitive, quantifiable signal that can be detected by eye or automated systems, enabling both high sensitivity and efficient throughput.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a sensitive and specific early diagnosis of invasive aspergillosis, improving diagnostic accuracy and overcoming limitations of existing methods by quantifying the ratio of IFN-γ and IL-10 producer T cells, thereby enhancing clinical detection and management of the infection.
Implementation Method 1
carrying out an in vitro immunoenzymatic ELISPOT assay wherein the biological fluid drawn from the patient is placed in contact with an antigen of Aspergillus fumigatus
Data Source
Figure 1A~1E
AI summary
The present invention refers to a method for the diagnosis and/or monitoring of the active or previous infection from Aspergillus fiimigatus which comprises carrying out an in vitro immunoenzymatic assay (ELISPOT) wherein the sample, from biological fluids drawn from the patient, is placed in contact with an antigen of Aspergillus fiimigatus.